# Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

> **NCT00927758** · PHASE2 · COMPLETED · sponsor: **Sandoz** · enrollment: 105 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg

## Key facts

- **NCT ID:** NCT00927758
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00927758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00927758, "Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00927758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*